May 13, 2026 7:00 am EDT Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
May 12, 2026 7:00 am EDT Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation
May 5, 2026 7:00 am EDT Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month
May 4, 2026 7:00 am EDT New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus
Apr 21, 2026 7:00 am EDT Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS
Apr 15, 2026 7:00 am EDT Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
Apr 10, 2026 7:00 am EDT Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year
Mar 27, 2026 9:05 am EDT Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
Mar 13, 2026 11:02 am EDT Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
